絞り込み

16421

広告

Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.

著者 Suzuki T , Kagami T , Uotani T , Yamade M , Hamaya Y , Iwaizumi M , Osawa S , Sugimoto K , Miyajima H , Furuta T
Eur J Clin Pharmacol.2017 Oct 06 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (68view , 0users)

Full Text Sources

Vonoprazan, a novel potassium-competitive acid blocker, elicits potent acid inhibition and hypergastrinemia at a dose of 20 mg. Its recommended maintenance dose for gastro-esophageal reflux disease is 10 mg, which is sometimes insufficient for preventing nocturnal acid breakthrough (NAB). Concomitant use of a histamine 2 receptor antagonist (H2RA) is effective for NAB. However, further acid inhibition by addition of H2RA has concern of hypergastrinemia again. Lafutidine (H2RA) is known to stimulate somatostatin release.
PMID: 28986609 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード